Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSAK trial of cediranib with saracatanib versus cediranib with placebo in relapsed clear cell renal cancer
ISRCTN56886343Phase 2Completed
- Sponsor
- NHS National Services Scotland
- Start
- Sep 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cediranib and saracatinib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by NHS National Services Scotland. Primary endpoint: Progression-free survival. Started Sep 2010; status: completed.
02
Drugs
cediranibsaracatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ISRCTN56886343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN56886343.